Investment Thesis • 0/10 sections
0/41 min0% complete

The True Enemy: Preventing Metastasis

The Problem: Over 90% of cancer-related deaths are not caused by the primary tumor, but by metastasis—the process by which cancer spreads to other parts of the body. The current medical paradigm is reactive, treating metastasis only after it's clinically detectable. We are missing the critical window to prevent it.

Our Solution: A strategic transformation from a simple research tool to the world's first AI-powered metastasis prevention system. We don't just provide data; we provide a predictive, proactive, and personalized strategy to stop metastasis before it starts.

0%

of cancer deaths caused by metastasis, not primary tumors

0

cancer deaths annually in US - most preventable

0

current solutions for metastasis prevention

Introducing: The Metastatic Potential Report

Instead of simple mutation lists, our platform generates a comprehensive, actionable report that provides oncologists with a roadmap to prevention. This is our core, revolutionary output.

Metastatic Risk Score

Stage-by-Stage Breakdown

Key Genetic Drivers

Prioritized Strategies

Pre-Designed Interventions

💡 Interactive Demo: Hover over each component above to see how our Metastatic Potential Report transforms cancer care from reactive to preventive.

The Patient's Broken Journey

Today's cancer care is reactive, fragmented, and often too late. We're building a proactive, integrated system that prevents metastasis before it starts.

The Old Way: Reactive & Fragmented

Treatment after the damage is done

Step 1

Genetic Testing

Patient receives genetic test results filled with Variants of Unknown Significance (VUS).

Key Problems:
  • 40-60% of results are VUS - clinically unusable
  • Months of waiting for unclear results
  • No actionable treatment guidance
Step 2

Clinical Confusion

Oncologist struggles to interpret ambiguous genetic data and make treatment decisions.

Key Problems:
  • Physicians spend 49% of time on administrative tasks
  • Limited genomic expertise in most practices
  • Treatment decisions based on incomplete information
Step 3

Trial & Error Treatment

Patient undergoes standard-of-care treatments that may not match their genetic profile.

Key Problems:
  • Average 3-4 treatment attempts before finding effective therapy
  • Precious time lost during cancer progression
  • Unnecessary toxicity from ineffective treatments
Step 4

Metastatic Progression

Without precision targeting, cancer metastasizes and becomes increasingly difficult to treat.

Key Problems:
  • 90% of cancer deaths are from metastasis
  • Limited treatment options once cancer spreads
  • Exponentially higher treatment costs

The CrisPRO Way: Proactive & Integrated

Prevention before progression

Step 1

Instant VUS Resolution

CrisPRO's Zeta Oracle immediately converts VUS into definitive, actionable insights.

CrisPRO Solutions:
  • Physics-based analysis provides definitive answers
  • Real-time results within minutes
  • Clear therapeutic recommendations
Step 2

Metastatic Risk Assessment

Our 8-step framework predicts metastatic potential and identifies intervention points.

CrisPRO Solutions:
  • Comprehensive metastatic pathway analysis
  • Stage-by-stage risk breakdown
  • Prioritized intervention strategies
Step 3

Precision Therapeutics

Zeta Forge designs personalized CRISPR interventions targeting patient-specific vulnerabilities.

CrisPRO Solutions:
  • Custom-designed therapeutic strategies
  • Pre-validated in digital twins
  • Optimal timing and dosing protocols
Step 4

Proactive Prevention

Treatment begins before metastasis occurs, dramatically improving outcomes.

CrisPRO Solutions:
  • Prevention-focused rather than reactive
  • Continuous monitoring and adaptation
  • Significantly improved survival rates

The Transformation

90%

Cancer deaths from metastasis

Prevention

Before metastasis occurs

Our Solution: The Pillars of Innovation

Our CrisPRO Oncology Co-Pilot is not a single tool, but a holistic ecosystem built on interconnected strategic pillars. This is our blueprint for victory.

Pillar 1: Information Dominance

Ingest and synthesize all patient data into a unified "Digital Twin" foundation.

Pillar 2: First-Principles Analysis

Annihilate VUS and provide deep biological context for every prediction.

Pillar 3: The Zeta Forge

Design, validate, and de-risk novel therapeutics `in silico`, compressing R&D.

Pillar 4: Predictive Digital Twins

Simulate tumor evolution and therapy response to identify resistance pathways early.

Pillar 5: AI-Orchestrated Logistics

Automate clinical operations and match patients to trials based on biological intent.

Pillar 6: The Triumvirate Checkpoint

An internal, automated validation system to ensure every output is not just powerful, but perfect.

Go-to-Market Strategy: A Multi-Front War

🎯

Pharma & Biotech

Lead with our Pre-Clinical Simulation Engine to de-risk their R&D pipeline and solve their >$2B per-drug failure problem.

🏥

Health Systems

Lead with our VUS Annihilation capability to provide immediate, undeniable clinical value and close their actionability gap.

🤝

Integrations

Embedding our platform as a 'premium intelligence layer' into EMRs and diagnostics.

🌐

DeSci & Web3

Pioneer IP-NFTs to raise non-dilutive R&D capital from Bio-DAOs and the Web3 community, creating a new funding paradigm.

5.0 A New Economic Engine: DeSci & Verification

We're not just building better therapeutics—we're creating an entirely new funding and verification paradigm that transforms how biotech innovation is financed and validated globally.

Traditional Funding Timeline

18-24 months

DeSci Funding Timeline

2-4 weeks

IP Liquidity Increase

10,000x

Global Investor Access

24/7

Step 1: IP-NFT Creation

We tokenize our therapeutic designs as IP-NFTs, creating liquid, tradeable intellectual property assets backed by real scientific value.

Step 2: Bio-DAO Partnerships

We partner with decentralized autonomous organizations focused on specific disease areas, leveraging their community and capital.

Step 3: Verification Layer

Our AI-powered verification system ensures the integrity and reproducibility of all research outputs, creating trust in the ecosystem.

Step 4: Global Liquidity

We create the world's first liquid market for biotech IP, enabling real-time price discovery and efficient capital allocation.

The DeSci Advantage

Why traditional biotech funding is broken and how we fix it

Traditional Problems:
  • 18-24 month funding cycles
  • Illiquid IP assets
  • Limited investor access
  • Opaque research processes
CrisPRO Solutions:
  • 2-4 week tokenized funding
  • 24/7 liquid IP markets
  • Global investor participation
  • AI-verified research integrity

The 8-Step Metastasis Framework: Our Clinical Roadmap

Our platform directly maps its analytical and generative capabilities to each critical step of cancer metastasis, providing a comprehensive, stage-by-stage intervention strategy.

1

Primary Tumor Growth

Driver mutation identification & essentiality scoring

2

Angiogenesis

VEGF pathway disruption strategies

3

EMT

Cell adhesion restoration & mobility prevention

4

Invasion

MMP enzyme knockout strategies

5

Circulation Survival

Immune visibility restoration

6

Homing

Receptor blinding strategies

7

Extravasation

Organ-specific targeting prevention

8

Dormancy Control

Forced hibernation induction

Interactive Framework: Click on any step above to explore detailed intervention strategies. This framework leverages our core endpoints to create a cohesive, actionable plan for metastasis prevention.

4.0 Business Model: Monetizing Metastatic Prevention

Our business model is designed to integrate seamlessly into the clinical oncology workflow, capturing value by providing an indispensable, first-of-its-kind decision support tool.

Oncology Market

$196B

Global oncology market size in 2023, growing at 7.5% CAGR

Precision Medicine

$86B

Precision medicine market, our direct addressable market

Cancer Diagnostics

$25B

Cancer diagnostics market, our immediate opportunity

Interactive Revenue Calculator

Clinical Decision Support

Per-report fee for Metastatic Potential Reports

101001000
Monthly Revenue:$50,000
Annual Revenue:$600,000

Target: Oncologists, Cancer Centers, Hospital Networks

Pharmaceutical Partnerships

API access and custom analysis for drug development

110100
Monthly Revenue:$25,000
Annual Revenue:$300,000

Target: Biotech & Pharmaceutical R&D Departments

Revenue Projection Summary

Projected Monthly Revenue

$75,000

Based on sliders above

Projected Annual Revenue

$900,000

12-month run rate

5-Year Potential

$11,250,000

Factoring in growth

5.0 Team: The Architects of Biological Innovation

Our founding team combines world-class expertise in CRISPR technology, AI/ML, and biotech commercialization. We are the rare team that can both envision and execute the future of precision medicine.

FJK

Fahad Kiani

Chief Technical and Executive Officer & Co-Founder

6 years experience

Fahad is a seasoned entrepreneur with a passion for using technology to improve healthcare. He is the co-founder of Jedilabs.org, a non-profit organization dedicated to advancing AI and ML in healthcare. Previosuly was a Senior Solutions Engineer at Talend, supporting enterprise customers around data integration and data governance. Led successful exits of 1stDibs and iMedicare as a founding team member.

CRISPRPrompt EngineeringComputational Biology+2 more
RN

Rahima Nayeem

Chief Clinical Officer & Co-Founder

8 years experience

Dr. Rahima Nayeem is an internist in New York and is affiliated with North Shore University Hospital at Northwell Health. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice between 6-10 years

Life ScienceChemistryPatient Care+1 more

8.0 The Call to Action

The oncology market is not a space for incremental improvement. The multi-trillion-dollar opportunity lies in providing definitive solutions. CrisPRO.ai is the only company with the technology, strategy, and vision to do so.

Section 1 of 10Executive Summary